Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Meningococcal Conjugate Vaccine (EuMCV4) in Healthy Adults
NCT04714229Phase 1Completed
- Sponsor
- EuBiologics
- Start
- Sep 2020
- Primary completion
- Nov 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of EuMCV4 in meningococcal infection (2 arms), sponsored by EuBiologics. Primary endpoints: Occurrence of solicited adverse events at 7 days, Occurrence of unsolicited adverse events at 28 days and 1 more. Started Sep 2020; status: completed.
02
Drugs
EuMCV4
03
Conditions
meningococcal infection
Beyond the preview
Go deeper on NCT04714229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04714229.